Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Sacituzumab govitecan plus pembrolizumab improves PFS across biomarker subgroups in metastatic triple-negative breast cancer

Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA
Sacituzumab govitecan plus pembrolizumab improves PFS across biomarker subgroups in metastatic triple-negative breast cancer ( Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA )
9 Jun 2026

1: Safe administration and dosing of EGFR inhibitors in NSCLC - Practical guidance for oncology nurses

Helena Ullgren, Rachel Powell, Irati Rodriguez-Matesanz and Elin Backman Stålnacke
1: Safe administration and dosing of EGFR inhibitors in NSCLC - Practical guidance for oncology nurses ( Helena Ullgren, Rachel Powell, Irati Rodriguez-Matesanz and Elin Backman Stålnacke )
8 Jun 2026

Personalised mRNA vaccine plus pembrolizumab shows durable benefit in high-risk melanoma

Dr Matteo S. Carlino - Westmead Hospital and Melanoma Institute Australia, Sydney, Australia
Personalised mRNA vaccine plus pembrolizumab shows durable benefit in high-risk melanoma ( Dr Matteo S. Carlino - Westmead Hospital and Melanoma Institute Australia, Sydney, Australia )
1 Jun 2026

ASCO 2026: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada
ASCO 2026: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )
1 Jun 2026

Velzatinib demonstrates broad activity across KIT mutations in advanced gastrointestinal stromal tumours

Dr Neeta Somaiah - The University of Texas MD Anderson Cancer Center, Houston, USA
Velzatinib demonstrates broad activity across KIT mutations in advanced gastrointestinal stromal tumours ( Dr Neeta Somaiah - The University of Texas MD Anderson Cancer Center, Houston, USA )
1 Jun 2026

Optimal panitumumab–bevacizumab sequencing evaluated in RAS wild-type metastatic colorectal cancer

Dr Ramón Salazar - The University of Barcelona, Barcelona, Spain
Optimal panitumumab–bevacizumab sequencing evaluated in RAS wild-type metastatic colorectal cancer ( Dr Ramón Salazar - The University of Barcelona, Barcelona, Spain )
1 Jun 2026

Relacorilant chemo combination extends OS in platinum-resistant ovarian cancer

Dr Lucy Gilbert - McGill University Health Centre, Montreal, Canada
Relacorilant chemo combination extends OS in platinum-resistant ovarian cancer ( Dr Lucy Gilbert - McGill University Health Centre, Montreal, Canada )
1 Jun 2026

Aspirin in stage III colorectal cancer shows no significant DFS benefit but favourable safety

Dr Atsuo Takashima - National Cancer Center Hospital, Tokyo, Japan
Aspirin in stage III colorectal cancer shows no significant DFS benefit but favourable safety ( Dr Atsuo Takashima - National Cancer Center Hospital, Tokyo, Japan )
1 Jun 2026

Short-term fasting linked to improved chemo response in advanced ovarian cancer

Dr Claudia Marchetti - Policlinico Universitario Agostino Gemelli, Rome, Italy
Short-term fasting linked to improved chemo response in advanced ovarian cancer ( Dr Claudia Marchetti - Policlinico Universitario Agostino Gemelli, Rome, Italy )
1 Jun 2026

ASCO 2026: Latest in prostate cancer

Prof Eleni Efstathiou, Prof Boris Hadaschik, Dr Mary-Ellen Taplin and Prof Axel Merseburger
ASCO 2026: Latest in prostate cancer ( Prof Eleni Efstathiou, Prof Boris Hadaschik, Dr Mary-Ellen Taplin and Prof Axel Merseburger )
1 Jun 2026

Amivantamab in HPV-unrelated mHNSCC gives high response rates after immunotherapy and chemo

Dr Barbara Burtness - Yale Cancer Center, New Haven, USA
Amivantamab in HPV-unrelated mHNSCC gives high response rates after immunotherapy and chemo ( Dr Barbara Burtness -  Yale Cancer Center, New Haven, USA )
1 Jun 2026

Gene expression test guided therapy in ER+/HER2- early breast cancer allows safe chemotherapy omission

Dr Robert Stein - University College London, London, UK
Gene expression test guided therapy in ER+/HER2- early breast cancer allows safe chemotherapy omission ( Dr Robert Stein - University College London, London, UK )
1 Jun 2026